SCHEMBL7762244

SCHEMBL7762244

CC(C)NC(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 9/20 0.69
DPP9 Q86TI2 9/20 0.69
DPP4 P27487 6/20 0.69
BLM P54132 2/20 0.52
ALOX15 P16050 1/20 0.52
PMP22 Q01453 1/20 0.52
KMT2A Q03164 1/20 0.52
DPP7 Q9UHL4 8/20 0.39
SLC15A1 P46059 1/20 0.38
ELANE P08246 1/20 0.38
GABRP O00591 2/20 0.34
GABRD O14764 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRB1 P18505 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34
GABRB2 P47870 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10940865 1.00 DPP8 (0.69) DPP8DPP9DPP4BLMALOX15
SCHEMBL30799779 0.85 DPP8 (0.65) DPP8DPP9DPP4BLMALOX15
SCHEMBL24322426 0.84 DPP8 (0.50) DPP8DPP9DPP4KMT2ADPP7
SCHEMBL10280921 0.84 DPP4 (0.69) DPP8DPP9DPP4BLMGABRP
SCHEMBL3065655 0.83 DPP4 (0.63) DPP8DPP9DPP4BLMALOX15
SCHEMBL751144 0.83 DPP4 (0.63) DPP8DPP9DPP4BLMALOX15
SCHEMBL10370366 0.82 DPP8 (0.61) DPP8DPP9DPP4BLMALOX15
SCHEMBL7947817 0.82 DPP8 (0.61) DPP8DPP9DPP4BLMALOX15
SCHEMBL7947818 0.82 DPP8 (0.61) DPP8DPP9DPP4BLMALOX15
SCHEMBL30910779 0.82 DPP4 (0.61) DPP8DPP9DPP4BLMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002242-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2022-01-06 US disclosed
US-10961189-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-03-30 US disclosed
US-20190161442-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-05-30 US disclosed
WO-2001073038-A2 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF L-ALANINOL LONZA AG (CH) 2001-10-04 WO disclosed
EP-0078152-B1 SALTS OF SULFODEHYDROABIETIC ACID AND TREATMENT OF GASTRO-INTESTINAL DISEASES Tanabe Seiyaku Co., Ltd. (JP) 1986-05-07 EP disclosed
US-4529602-A Sulfodehydroabietic acid compound TANABE SEIYAKU CO., LTD. (JP) 1985-07-16 US disclosed
EP-0078152-A1 Salts of sulfodehydroabietic acid and treatment of gastro-intestinal diseases Tanabe Seiyaku Co., Ltd. (JP) 1983-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161442-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A DPP8 1501/4885DPP9 2104/4885DPP4 2195/4885
US-10961189-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A DPP8 1501/4885DPP9 2104/4885DPP4 2195/4885
US-20220002242-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A DPP8 1501/4885DPP9 2104/4885DPP4 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.